1.Exacerbation of Emesis and Dysphagia with Oxycodone Dose Escalation in a Patient with Lung Cancer, Possibly Associated with Complicated Esophageal Achalasia
Masahito Muramatsu ; Daisaku Nishimura ; Atsushi Masuda ; Tomoyuki Tsuzuki ; Natsuko Uematsu ; Saya Tanaka ; Yu Kondo
Palliative Care Research 2016;11(3):538-542
Objective: We describe a case of lung cancer complicated with esophageal achalasia (EA), which was successfully treated with endoscopic pneumatic dilation (EPD). Case: A 66-year-old woman was admitted to our hospital because of frequent episodes of emesis and dysphagia after receiving an escalating dose of sustained release oxycodone (SRO) for cancer-related multifactorial back pain. She had been diagnosed with EA and treated with EPD at the age of 50. Her symptoms were refractory to the conventional anti-emetic agents such as prochlorperazine and metoclopramide. Computed tomography imaging showed marked dilatation of the esophagus with food residue. We diagnosed EA based on the presence of rosette-like esophageal folds on endoscopy and narrowing of the esophagogastric junction on esophagography, and subsequently performed EPD, which alleviated the symptoms. Discussion: The effects of opioids on esophageal motility have not been elucidated thus far. Recent studies using high-resolution manometry reported that long-term use of opioids was associated with esophageal dysmotility similar to that observed in EA. Although we have no evidence to directly demonstrate the causal relationship between the use of SRO and anti-emetic agents and EA, we speculate that our patient’s symptoms might be associated not only with SRO-related emesis during the gradual worsening of EA, but also partly with the SRO-induced esophageal dysmotility and the constrictive effect of dopamine D2 receptor antagonists on the lower esophageal sphincter. Care must be taken to avoid drug-induced esophageal motor dysfunction, which might lead to deteriorate EA.
2.Successful Continuous Irrigation for Methicillin-Resistant Staphylococcus aureus Mediastinitis after Open Heart Surgery in an Infant with Hypoplastic Left Heart Syndrome.
Atsushi Ito ; Kozo Ishino ; Masaaki Kawada ; Gentaro Kato ; Tomohiro Asai ; Yu Ohshima ; Zen-ichi Masuda ; Shunji Sano
Japanese Journal of Cardiovascular Surgery 2002;31(3):214-216
A 2-month-old boy developed Methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis after bidirectional Glenn anastomosis for hypoplastic left heart syndrome. After reexploration, only the skin was closed but the sternum left open, and continuous mediastinal irrigation using saline containing isodine was commenced at an infusion rate of 20-40ml/h. The sternum was closed on day 7 and irrigation was stopped on day 21. The patient was weaned from the ventilator 4 days later, and is currently in a good condition awaiting a Fontan operation.
3.Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke HIZUKA ; Shin-ichiro HAGIWARA ; Ryutaro SAURA ; Yu MASUDA ; Ayaha HATA ; Takatoshi MAEYAMA ; Yuri ETANI
Pediatric Gastroenterology, Hepatology & Nutrition 2025;28(3):176-184
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children’s hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
4.Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke HIZUKA ; Shin-ichiro HAGIWARA ; Ryutaro SAURA ; Yu MASUDA ; Ayaha HATA ; Takatoshi MAEYAMA ; Yuri ETANI
Pediatric Gastroenterology, Hepatology & Nutrition 2025;28(3):176-184
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children’s hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
5.Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke HIZUKA ; Shin-ichiro HAGIWARA ; Ryutaro SAURA ; Yu MASUDA ; Ayaha HATA ; Takatoshi MAEYAMA ; Yuri ETANI
Pediatric Gastroenterology, Hepatology & Nutrition 2025;28(3):176-184
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children’s hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
6.Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke HIZUKA ; Shin-ichiro HAGIWARA ; Ryutaro SAURA ; Yu MASUDA ; Ayaha HATA ; Takatoshi MAEYAMA ; Yuri ETANI
Pediatric Gastroenterology, Hepatology & Nutrition 2025;28(3):176-184
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children’s hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
7.Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke HIZUKA ; Shin-ichiro HAGIWARA ; Ryutaro SAURA ; Yu MASUDA ; Ayaha HATA ; Takatoshi MAEYAMA ; Yuri ETANI
Pediatric Gastroenterology, Hepatology & Nutrition 2025;28(3):176-184
Purpose:
Functional dyspepsia (FD) is a chronic disorder characterized by upper abdominal symptoms in the absence of an identifiable organic cause. Although the efficacy of acotiamide has been demonstrated in adults with FD, its effectiveness in pediatric patients remains unclear. This study aimed to evaluate the efficacy of acotiamide in pediatric patients with FD.
Methods:
We conducted a retrospective analysis of 33 patients with FD, aged <16 years, who received acotiamide at a single children’s hospital between August 2013 and March 2022.
Results:
Symptomatic improvement was observed in 57.6% (19/33) of patients one month after acotiamide administration. The improvement rates were 63.6%, 20.0%, and 66.7% among patients with epigastric pain syndrome (EPS), postprandial distress syndrome (PDS), and overlap PDS-EPS, respectively. No statistically significant differences in symptomatic improvement rates were noted among the subtypes (p=0.213). Two patients discontinued acotiamide because of abdominal pain, but no serious adverse events were reported.
Conclusion
Acotiamide demonstrated efficacy in pediatric FD, which is consistent with previously reported outcomes in adults. Acotiamide may be a beneficial treatment option for pediatric FD across all subtypes.
8.Hokkaido birth cohort study on environment and children's health: cohort profile 2021.
Reiko KISHI ; Atsuko IKEDA-ARAKI ; Chihiro MIYASHITA ; Sachiko ITOH ; Sumitaka KOBAYASHI ; Yu AIT BAMAI ; Keiko YAMAZAKI ; Naomi TAMURA ; Machiko MINATOYA ; Rahel Mesfin KETEMA ; Kritika POUDEL ; Ryu MIURA ; Hideyuki MASUDA ; Mariko ITOH ; Takeshi YAMAGUCHI ; Hisanori FUKUNAGA ; Kumiko ITO ; Houman GOUDARZI
Environmental Health and Preventive Medicine 2021;26(1):59-59
BACKGROUND:
The Hokkaido Study on Environment and Children's Health is an ongoing study consisting of two birth cohorts of different population sizes: the Sapporo cohort and the Hokkaido cohort. Our primary objectives are to (1) examine the effects that low-level environmental chemical exposures have on birth outcomes, including birth defects and growth retardation; (2) follow the development of allergies, infectious diseases, and neurobehavioral developmental disorders, as well as perform a longitudinal observation of child development; (3) identify high-risk groups based on genetic susceptibility to environmental chemicals; and (4) identify the additive effects of various chemicals, including tobacco.
METHODS:
The purpose of this report is to provide an update on the progress of the Hokkaido Study, summarize recent results, and suggest future directions. In particular, this report provides the latest details from questionnaire surveys, face-to-face examinations, and a collection of biological specimens from children and measurements of their chemical exposures.
RESULTS:
The latest findings indicate different risk factors of parental characteristics on birth outcomes and the mediating effect between socioeconomic status and children that are small for the gestational age. Maternal serum folate was not associated with birth defects. Prenatal chemical exposure and smoking were associated with birth size and growth, as well as cord blood biomarkers, such as adiponectin, leptin, thyroid, and reproductive hormones. We also found significant associations between the chemical levels and neuro development, asthma, and allergies.
CONCLUSIONS
Chemical exposure to children can occur both before and after birth. Longer follow-up for children is crucial in birth cohort studies to reinforce the Developmental Origins of Health and Disease hypothesis. In contrast, considering shifts in the exposure levels due to regulation is also essential, which may also change the association to health outcomes. This study found that individual susceptibility to adverse health effects depends on the genotype. Epigenome modification of DNA methylation was also discovered, indicating the necessity of examining molecular biology perspectives. International collaborations can add a new dimension to the current knowledge and provide novel discoveries in the future.
Biomarkers/blood*
;
Child
;
Child Health
;
Child, Preschool
;
Cohort Studies
;
Environmental Exposure/adverse effects*
;
Environmental Health
;
Environmental Pollutants/adverse effects*
;
Female
;
Fetal Blood/chemistry*
;
Follow-Up Studies
;
Growth/drug effects*
;
Humans
;
Hypersensitivity/etiology*
;
Infant
;
Japan/epidemiology*
;
Male
;
Neurodevelopmental Disorders/etiology*
;
Pregnancy
;
Prenatal Exposure Delayed Effects/etiology*
;
Prevalence
;
Smoking/adverse effects*